Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

2014 ◽  
Vol 75 (1) ◽  
pp. 111-121 ◽  
Author(s):  
Eleonora Marostica ◽  
Juthamas Sukbuntherng ◽  
David Loury ◽  
Jan de Jong ◽  
Xavier Woot de Trixhe ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
B Cell ◽  
Tyrosine Kinase Inhibitor ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Kinase Inhibitor ◽  
Population Pharmacokinetic ◽  
B Cell Malignancies ◽  
Bruton Tyrosine Kinase

Chemorefractory Diffuse Large B-Cell Lymphoma- is a Cure Possible with Bruton Tyrosine Kinase Inhibitor?

2021 ◽  
Author(s):  
Purnima Sravanti Teegavarapu ◽  
Monira Haque ◽  
Andreia Barbieri ◽  
Gustavo Rivero ◽  
Martha Mims
Keyword(s):  
Tyrosine Kinase ◽  
B Cell ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Bruton Tyrosine Kinase ◽  
Large B Cell

Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies

2021 ◽  
pp. 1-8
Author(s):  
Wojciech Jurczak ◽  
Simon Rule ◽  
William Townsend ◽  
David Tucker ◽  
Barbara Sarholz ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
B Cell ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
B Cell Malignancies ◽  
Bruton's Tyrosine Kinase ◽  
Human Trial
Sign in / Sign up

Export Citation Format

Share Document